Clinical and translational gastroenterologyOct 6, 2026

US Healthcare Professionals' Management of Fatty Liver Disease and Knowledge of Hormone-Based Diabetes Treatments

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 7, 2026

Abstract

Investigational agents targeting GLP-1R, GIPR, and GCGR are being evaluated for treating metabolic liver diseases.

Healthcare professionals perceive the potential of these agents in addressing metabolic dysfunction-associated liver diseases.
Combinations of these receptor agonists may offer new therapeutic options for managing MASLD and MASH.
Understanding HCPs' perspectives could inform future clinical strategies for patient care.

Simplified

Various combinations of agonists of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) are in clinical trials for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We explored how US healthcare professionals (HCPs) treating people with MASLD/MASH perceive these investigational agents.

Full Text

Full text is available at the source.

View Full Text ↗

US Healthcare Professionals' Management of Fatty Liver Disease and Knowledge of Hormone-Based Diabetes Treatments

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief